NeuroVive Pharmaceutical AB Revenu Q/Q
Quel est le Revenu Q/Q de NeuroVive Pharmaceutical AB?
Le Revenu Q/Q de NeuroVive Pharmaceutical AB est -63.53%
Quelle est la définition de Revenu Q/Q?
La croissance trimestrielle du chiffre d'affaires, d'une année sur l'autre , correspond à l'augmentation du chiffre d'affaires d'une entreprise par rapport à la performance du trimestre correspondant d'un exercice précédent, exprimée en pourcentage.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenu Q/Q des entreprises dans Health Care secteur sur OTC par rapport à NeuroVive Pharmaceutical AB
Que fait NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Entreprises avec revenu q/q similaire à NeuroVive Pharmaceutical AB
- XXL a Revenu Q/Q de -63.64%
- Mosaic Brands a Revenu Q/Q de -63.63%
- Sundance a Revenu Q/Q de -63.61%
- Urban&Civic plc a Revenu Q/Q de -63.56%
- Pioneer Embroideries a Revenu Q/Q de -63.55%
- u-blox AG a Revenu Q/Q de -63.54%
- NeuroVive Pharmaceutical AB a Revenu Q/Q de -63.53%
- Remsons Industries a Revenu Q/Q de -63.52%
- AYM Syntex a Revenu Q/Q de -63.44%
- Conscience Capital a Revenu Q/Q de -63.39%
- Jolimark a Revenu Q/Q de -63.36%
- Cntrl China New Life Ltd a Revenu Q/Q de -63.36%
- Larry Jewelry International a Revenu Q/Q de -63.35%